Investing Center Preview – Manage your investments and watch your net worth grow.
JAGX:NASDAQ – Small Cap Stock (Biotechnology)
Jaguar Health Inc – JAGX Stock Overview
Last Price | Today's Change | 52-Week Range | Trading Volume |
---|---|---|---|
5.05 | 0.33 (+6.89%) | 4.02 - 540.00 | 27.7 thousand (Below Avg) |
Market data as of 3:58PM 04/09/25. Quotes are delayed by at least 15 min.
Overview - JAGX
Open | 4.84 |
---|---|
Previous Close | 4.72 |
Day's Range | 4.51 - 5.14 |
Market Cap | 3.4M |
Avg Volume (10 Day) | 30.6K |
Price/Earnings (Trailing 12 Mo.) | -- |
Earnings Per Share (Trailing 12 Mo.) | -4058.4163 |
Dividend Yield | No Dividend |
One-Click Scorecard - JAGX


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Performed well consistently? | Fail |
---|---|
Avoids excess debt? | Fail |
Converting sales to profits? | Fail |
Shareholder's money handled rationally? | Neutral |
Increased shareholder value? | Neutral |
Consistently increased owner earnings? | Fail |
Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Pays a cash dividend? | Neutral |
---|---|
Room to increase dividends? | Fail |
Increased earnings over time? | Neutral |
Borrows within reasonable limits? | Fail |
Stock is undervalued? | Fail |
Have investors caught on? | Fail |
Has support of institutional investors? | Fail |
Has sufficient liquidity? | Pass |
Latest Headlines - JAGX
No news headlines available for JAGX
Industry Position - JAGX
JAGX | Industry Range | |
---|---|---|
Revenue Growth (1yr) | 19.75% | |
Net Income Growth (1yr) | -- | |
Total Debt/Equity | 5.01 | |
LT Debt/Equity | 3.32 | |
Earnings Yield | -- | |
Price/Sales | 0.12 |
Competitors - JAGX
Company | Last | Change |
---|---|---|
Genprex Inc | 0.28 | +8.06% |
Protagenic Therapeutics Inc | 0.27 | -2.66% |
Affymax Inc | 0.00 | 0.00% |
180 Life Sciences Corp | 0.75 | +1.54% |
Scisparc Ltd | 0.28 | -2.29% |
Data is delayed by at least 15 min.